Navigation Links
Increased Heart Attack Risk From Celebrex,Vioxx

CELEBREX (celecoxib capsules) is used for relief of the pain and inflammation of osteoarthritis and adult rheumatoid arthritis. By effectively reducing the pain, inflammation and stiffness of arthritis, celebrex can help you through the day with activities like standing, walking or climbing stairs, and through the night while sitting or lying in bed.

Since their introduction in 1999, the drugs, which are known technically as COX-2 inhibitors, have been among // America's best-selling prescription pharmaceuticals. One of them, Celecoxib, sold as Celebrex, was the sixth leading prescription drug used by 14 million people last year. The other COX-2 inhibitor is Rofecoxib, sold as Vioxx.

The drugs are popular because they provide the same pain- killing effects as aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen, but with less chance of causing ulcers and intestinal bleeding.

Aspirin inhibits two closely related cyclooxygenase enzymes, COX-1 and COX-2. These new drugs specifically inhibit only the COX-2 (which is involved in pain and inflammation) while not affecting the first (which is involved in protecting lining of the stomach).

Celebrex, was recently approved by the Food and Drug Administration, FDA. The popular pain-killers Celebrex and Vioxx may slightly increase a person's risk of having a heart attack, according to an analysis of clinical studies of these 'super aspirin' drugs.


'"/>




Page: 1

Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Allergy Risk Increased by Kerosene Use
3. Fewer teeth & Increased Ischemic Stroke risk
4. Young Smokers at Increased Risk Of Developing a Heart Attack
5. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
6. Asbestos Exposure Associated With An Increased Risk For Autoimmune Disease
7. Schizophrenics On Medication At An Increased Risk For Developing Diabetes
8. Diabetics Found To Be At An Increased Risk Of Developing Cancer
9. Increased Risk For Venous Thrombosis In Cancer Patients
10. Increased risk of common infections in patients suffering from diabetes
11. Infertility Associated With Increased Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: